Adenuric (febuxostat) coated tablets 80 mg. №28

Description

Composition

active substance: febuxostat;

1 film-coated tablet contains febuxostat 80 mg;

auxiliary substances: lactose monohydrate, hydroxypropyl cellulose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal aqueous silicon dioxide, polyvinyl alcohol, titanium dioxide (E 171), polyethylene glycol, talc, iron oxide yellow (E 172).

Pharmacodynamics

Uric acid is the end product of purine metabolism in humans and is produced by the following reaction: hypoxanthine → xanthine → uric acid. Xanthine oxidase catalyzes both steps of this reaction. Febuxostat is a derivative of 2-arylthiazole. Its therapeutic effect is associated with a decrease in the concentration of uric acid in the blood serum by selective suppression of xanthine oxidase. Febuxostat is a potent and selective non-purine inhibitor of xanthine oxidase (NP-SIXO) with an in vitro inhibitory constant (Ki) of <1 nanomolar. Febuxostat has been shown to significantly inhibit the activity of both the oxidized and reduced forms of xanthine oxidase. At therapeutic concentrations, febuxostat does not affect other enzymes involved in the metabolism of purines or pyrimidines, such as guanine deaminase, hypoxanthine guanine phosphoribosyl transferase, orotate phosphoribosyl transferase, orotidine monophosphate decarboxylase, or purine nucleoside phosphorylase.

Indications

Adenuric treatment of chronic hyperuricemia in patients with diseases accompanied by the deposition of urate crystals, including those with tophi and / or gouty arthritis at present or in history.

Application of Adenuric

Gout. The recommended dose of Adenuric is 80 mg orally once daily, with or without food. If the concentration of uric acid in the blood serum exceeds 6 mg / dl (357 μmol / l) after 2-4 weeks of treatment, the dose of Adenuric can be increased to 120 mg 1 time per day.

The duration of prevention of gout attacks is at least 6 months.

The effect of the drug occurs quite quickly, which makes it possible to re-determine the concentration of uric acid after 2 weeks. The goal of treatment is to lower the serum uric acid concentration and maintain it at a level of <6 mg/dL (357 µmol/L).

Contraindications

Hypersensitivity to the active substance or any other auxiliary component of the drug.